Statement by Indian Pharmaceutical Alliance (IPA)

Product Integrity & Patient Safety Commitment

The Indian Pharmaceutical Alliance (IPA), a premier association representing Indian pharmaceutical industry, emphasizes our commitment to upholding the highest standards of product quality and integrity, which are fundamental for patient safety and public trust.

Indian companies, many of whom are global brands and manufacturers of affordable medicines, account for approximately 40% of the U.S. prescription, 25% of EU and around 20% contribution to the world. Standing as the third-largest country in pharmaceutical volume, we are proud of our significant contribution to affordable quality-assured medicine, serving and advancing patient health outcomes globally.

At IPA, our unwavering commitment to quality and safety is paramount. We support robust quality control measures, including unannounced inspections, rigorous manufacturing standards, and adherence to the highest global benchmarks. As IPA, we have spearheaded a unique Quality Forum from 2015 onwards that has focused on knowledge development, capability building and cross industry/industry-academia collaboration to share best practices and consistently look for avenues to advance our manufacturing practices. Our investment in an Institute for Quality reflects our dedication to advancing pharmaceutical quality through research, education, and best practices.

We recognize that maintaining high-quality standards is a global challenge, not confined to any specific country or region. Any adverse incidents underscore the need for prompt and decisive regulatory action, reinforcing adherence to stringent industry-wide standards and practices by all pharmaceutical companies doing business in India, U.S., E.U., and around the globe.

Ensuring patient safety and maintaining product integrity are at the forefront of our mission. We are dedicated to collaborating with policymakers, industry peers, healthcare providers, and consumers to fortify supply chain resilience, enhance transparency, and ensure the availability of quality, affordable medicines.

IPA is committed to providing quality medicines to patients in India and across globe as patient centricity and their welfare is fundamental to us.

Sudarshan Jain
Secretary General
Indian Pharmaceutical Alliance

Indian Pharmaceutical Alliance (IPA) represents 25 large Indian pharmaceutical companies. Innovation, Quality and Reach are the primary focus areas of IPA with patient at the center of our endeavours. IPA’s mission is to make quality medicines available, accessible and affordable to people across the world. For more details, please refer www.ipa-india.org